Brimonidine (EENT)

Drug class: Antineoplastic Agents

Usage of Brimonidine (EENT)

Ocular Hypertension and Glaucoma

Brimonidine tartrate 0.1, 0.15, and 0.2%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Ocular hypotensive effect of the 0.1 or 0.15% solution is equivalent to that of the 0.2% solution; reduction in IOP was approximately 2–6 mm Hg in clinical studies.

Fixed-combination Brinzolamide 1% and brimonidine tartrate 0.2%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. When administered 3 times daily, IOP-lowering effect was 1–3 mm Hg greater than that of either drug administered at the same dosage as monotherapy.

Fixed-combination brimonidine tartrate 0.2% and timolol 0.5%: Used topically in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy because of inadequately controlled IOP. When administered twice daily, IOP-lowering effect was 1–3 mm Hg greater than that of brimonidine tartrate 0.2% administered 3 times daily, 1–2 mm Hg greater than that of timolol 0.5% administered twice daily, and approximately 1–2 mm Hg less than that achieved with concurrent use of brimonidine tartrate 0.2% administered 3 times daily and timolol 0.5% administered twice daily.

When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost). With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostaglandin analogs; 20–25% with topical β-adrenergic blocking agents, α-adrenergic agonists, or miotic (parasympathomimetic) agents; 20–30% with oral carbonic anhydrase inhibitors; 18% with topical rho kinase inhibitors; and 15–20% with topical carbonic anhydrase inhibitors.

A prostaglandin analog frequently is considered for initial therapy in the absence of other considerations (e.g., contraindications, cost considerations, intolerance, adverse effects, patient refusal) because of relatively greater activity, once-daily administration, and low frequency of systemic adverse effects; however, ocular adverse effects can occur.

Goal is to maintain an IOP at which visual field loss is unlikely to substantially reduce quality of life during the patient's lifetime.

Reduction of pretreatment IOP by ≥25% shown to slow progression of primary open-angle glaucoma. Set an initial target IOP (based on extent of optic nerve damage and/or visual field loss, baseline IOP at which damage occurred, rate of progression, life expectancy, and other considerations) and reduce IOP toward this goal. Adjust target IOP up or down as needed over course of disease.

Combination therapy with drugs from different therapeutic classes often required to control IOP.

Conjunctival Congestion

Brimonidine tartrate 0.025%: Self-medication for temporary relief of ocular redness due to minor irritation.

No evidence of tachyphylaxis in clinical studies, and minimal rebound ocular congestion observed following drug discontinuance.

Relate drugs

How to use Brimonidine (EENT)

General

  • When used for ocular hypertension or glaucoma, determine IOP after about 4 weeks of therapy with the drug; thereafter, determine IOP as necessary.

    • Administration

    Ophthalmic Administration

    Apply topically to the affected eye(s) as an ophthalmic solution (brimonidine alone or in fixed combination with timolol) or suspension (fixed-combination brinzolamide and brimonidine).

    Shake the ophthalmic suspension well prior to administration of each dose.

    Avoid contamination of the dispensing container. (See Bacterial Keratitis under Cautions.)

    Some preparations contain benzalkonium chloride. Remove contact lenses before administering each dose of these preparations; may reinsert lenses 15 minutes after the dose. Manufacturer of brimonidine tartrate 0.025% ophthalmic solution states contact lenses may be reinserted 10 minutes after the dose. (See Use with Contact Lenses under Cautions.)

    If more than one topical ophthalmic preparation is used, administer the preparations at least 5 minutes apart.

    Dosage

    Pediatric Patients

    Ocular Hypertension and Glaucoma Ophthalmic

    Brimonidine tartrate 0.1, 0.15, or 0.2% ophthalmic solution in pediatric patients ≥2 years of age: Manufacturer makes no specific dosage recommendations. (See Pediatric Use under Cautions.)

    Brimonidine tartrate 0.2% and timolol 0.5% ophthalmic solution in pediatric patients ≥2 years of age: One drop in the affected eye(s) twice daily (approximately every 12 hours).

    Conjunctival Congestion Ophthalmic

    Brimonidine tartrate 0.025% ophthalmic solution in pediatric patients ≥5 years of age: One drop in the affected eye(s) every 6–8 hours.

    Adults

    Ocular Hypertension and Glaucoma Ophthalmic

    Brimonidine tartrate 0.1, 0.15, or 0.2% ophthalmic solution: One drop in the affected eye(s) 3 times daily (approximately every 8 hours).

    Brinzolamide 1% and brimonidine tartrate 0.2% ophthalmic suspension: One drop in the affected eye(s) 3 times daily.

    Brimonidine tartrate 0.2% and timolol 0.5% ophthalmic solution: One drop in the affected eye(s) twice daily (approximately every 12 hours).

    If target IOP not achieved, may initiate additional or alternative ocular hypotensive agents. (See Ocular Hypertension and Glaucoma under Uses.)

    Conjunctival Congestion Ophthalmic

    Brimonidine tartrate 0.025% ophthalmic solution: One drop in the affected eye(s) every 6–8 hours.

    Prescribing Limits

    Pediatric Patients

    Conjunctival Congestion Ophthalmic

    Brimonidine tartrate 0.025% ophthalmic solution: Maximum of 4 times daily.

    Adults

    Conjunctival Congestion Ophthalmic

    Brimonidine tartrate 0.025% ophthalmic solution: Maximum of 4 times daily.

    Warnings

    Contraindications

  • Neonates and infants <2 years of age. (See Pediatric Use under Cautions.)
  • Known hypersensitivity to brimonidine or any ingredient in the formulation.

    • Warnings/Precautions

    Sensitivity Reactions

    Hypersensitivity Reactions

    Ocular hypersensitivity reactions (e.g., allergic conjunctivitis, conjunctival hyperemia, ocular pruritus) reported. If sensitivity reaction occurs, discontinue brimonidine.

    Possible partial cross-sensitivity between brimonidine and apraclonidine; use with caution in patients with a history of hypersensitivity to apraclonidine.

    Use of Fixed Combinations

    When used in fixed combination with timolol or brinzolamide, consider the cautions, precautions, contraindications, and drug interactions associated with each agent in the fixed combination.

    Cardiovascular Disease

    Minimal effects on BP in clinical studies; however, use with caution in patients with severe cardiovascular conditions.

    Vascular Insufficiency

    May potentiate syndromes associated with vascular insufficiency; use with caution in patients with mental depression, orthostatic hypotension, cerebral or coronary insufficiency, Raynaud phenomenon, or thromboangiitis obliterans.

    IOP Monitoring

    IOP-lowering effect of brimonidine may diminish over time; routinely monitor IOP.

    Bacterial Keratitis

    Bacterial keratitis reported with use of multiple-dose containers of topical ophthalmic preparations. Containers were inadvertently contaminated by patients, most of whom had concurrent corneal disease or disruption of the ocular epithelial surface.

    Improper handling of ophthalmic preparations can result in contamination of the preparation by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated ophthalmic preparations. (See Advice to Patients.)

    Use with Contact Lenses

    Some Brimonidine ophthalmic preparations contain benzalkonium chloride, which may be absorbed by soft contact lenses. Remove contact lenses before administering each dose of these preparations; may reinsert lenses 15 minutes after the dose. Manufacturer of brimonidine tartrate 0.025% ophthalmic solution states contact lenses may be reinserted 10 minutes after the dose.

    Specific Populations

    Pregnancy

    Category B.

    In studies in animals, brimonidine crossed the placenta and entered the fetal circulation to a limited extent; no evidence of teratogenicity was observed.

    No adequate and well-controlled studies in pregnant women. Use brimonidine only if potential benefits justify possible risk to the fetus.

    Lactation

    Distributed into milk in rats; not known whether distributed into human milk following topical application to the eye. Discontinue nursing or the drug.

    Pediatric Use

    Potentially serious adverse effects, including apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence, reported in infants; contraindicated in infants <2 years of age.

    Safety and efficacy of topical brimonidine for treatment of open-angle glaucoma or ocular hypertension not established in pediatric patients <2 years of age. In children 2–7 years of age with glaucoma, the most common adverse effects of brimonidine (0.2% solution administered 3 times daily) were somnolence and decreased mental alertness; approximately 16% of children discontinued therapy because of somnolence. Incidence of somnolence appeared to be age and weight related, occurring in 50–83% of children 2–6 years of age and 25% of those 7 years of age who weighed >20 kg.

    The individual components of brinzolamide and brimonidine ophthalmic suspension have been studied in pediatric patients 4 weeks to 5 years of age (brinzolamide) and 2–7 years of age (brimonidine).

    Safety and efficacy of Brimonidine and timolol ophthalmic solution established in pediatric patients 2–16 years of age based on evidence from adequate and well-controlled studies of the fixed combination in adults and additional data from a study evaluating the individually administered drugs (brimonidine tartrate 0.2% administered 3 times daily as an adjunct to timolol therapy) in children 2–7 years of age with glaucoma.

    Safety and efficacy of topical brimonidine for self-medication for relief of ocular redness due to minor irritation not established in children <5 years of age. Safety and efficacy in pediatric patients ≥5 years of age are supported by evidence from controlled clinical trials in adults and additional data from a safety study in adults and pediatric patients ≥5 years of age.

    Geriatric Use

    No substantial differences in safety and efficacy relative to younger adults.

    Hepatic Impairment

    Not been studied in patients with hepatic impairment; use with caution.

    Renal Impairment

    Not studied in patients with renal impairment.

    Common Adverse Effects

    Brimonidine tartrate 0.1–0.2% ophthalmic solution: Oral dryness, ocular or conjunctival hyperemia, burning and stinging, allergic conjunctivitis, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, ocular pruritus.

    Brimonidine tartrate 0.2% ophthalmic solution in children 2–7 years of age with glaucoma: Age- and weight-related somnolence and decreased mental alertness reported. (See Pediatric Use under Cautions.)

    Brimonidine tartrate 0.025% ophthalmic solution in adults and pediatric patients: Decreased visual acuity, conjunctival or ocular hyperemia, dry eye, instillation site pain, headache.

    What other drugs will affect Brimonidine (EENT)

    No formal drug interaction studies have been performed.

    Specific Drugs

    Drug

    Interaction

    Comment

    β-Adrenergic blocking agents (topical or systemic)

    Possible additive IOP-lowering and cardiovascular effects

    Use with caution

    Increased IOP-lowering effect used to therapeutic advantage

    Antidepressants, tricyclic (TCAs)

    TCAs that affect the metabolism and uptake of circulating amines may interfere with IOP-lowering effect of brimonidine

    Use with caution

    Cardiac glycosides

    Possible additive cardiovascular effects

    Use with caution

    CNS depressants (e.g., alcohol, barbiturates, general anesthetics, opiates, sedatives)

    Possible additive CNS depressant effects

    Hypotensive agents

    Possible additive IOP-lowering and cardiovascular effects

    Use with caution

    MAO inhibitors

    Theoretical potential for interference with brimonidine metabolism, possibly resulting in increased systemic adverse effects (e.g., hypotension)

    Use with caution

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant